{"schema_version":"secwatch.filing_event.v1","accession":"0001798749-23-000013","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.581036+00:00","generated_at":"2026-06-17T10:47:42.240990+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aerovate reports FY2022 net loss of $51.5M; cash runway into H2 2025","bullets":["Net loss of $51.5M for FY2022 vs $23.0M in FY2021; R&D expenses $38.6M (up from $15.0M).","Cash, cash equivalents and investments $129.2M as of Dec 31, 2022; sufficient to fund operations into H2 2025.","IMPAHCT Phase 2b/3 trial of AV-101 for PAH ongoing; topline data expected Q4 2023 or Q1 2024.","Four patents issued in 2022; management team strengthened with four new SVPs.","Board appointed Donald Santel; expanded IP portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001798749-23-000013","json":"https://secwatch.observer/filing/0001798749-23-000013.json","markdown":"https://secwatch.observer/filing/0001798749-23-000013.md","text":"https://secwatch.observer/filing/0001798749-23-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000013/0001798749-23-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000013/tmb-20230329x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:47:42.240990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94c594522a7708ce8a61e160205ba6444c1357e8","claim":"Jade Biosciences, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 29, 2023, Aerovate Therapeutics, Inc. announced its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000013/0001798749-23-000013-index.htm","confidence":0.6,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}